LHLabcorp
$312.23+14% 1Y
$312.23
$244.6952 weeks$339.57
The financials
Labcorp by the numbers
Labcorp (LH) reported revenue of $3.73B in Q2 2026 (quarter ended Jun 30, 2026), up 5.8% from the same quarter a year earlier. That came with a gross margin of 30% and net income of $299M (8.0% of revenue). For the full year FY2025, revenue was $14.0B (+7.2% year on year) and net income $877M. Its largest segment in Q2 2026 was Diagnostics at $2.90B, 78% of the disclosed total, well ahead of Biopharma Laboratory Services at 22%. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $3.73B | $3.53B | +5.8% |
| Gross profit | $1.11B | $1.05B | +6.3% |
| Operating income | $452M | $395M | +14% |
| Net income | $299M | $238M | +26% |
| Diluted EPS | $3.64 | $2.84 | +28% |
| Operating | Revenue | Share |
|---|---|---|
| Diagnostics | $2.90B | 78% |
| Biopharma Laboratory Services | $836M | 22% |
Business segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Jun 2026Total $3.74B (+5.5%)
Biopharma Laboratory Services grew +6.5% year on yearDiagnostics +5.5% year on year
Segment Latestquarter on quarteryear on year
- Diagnostics$2.90B$2.90Bquarter on quarter +5.0%year on year +5.5%+5.0%+5.5%
- Biopharma Laboratory Services$836.2M$836.2Mquarter on quarter +7.1%year on year +6.5%+7.1%+6.5%
On our screens:Quality at a reasonable price
Diagnostics & Research
The closest names by size in the same industry